Randomised withdrawal is the cleanest design in this field and the least discussed
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
Harriet Oduya
Page 4 of 10 of this archive, newest first.
Archive — page 4
192 piecesA year after stopping: what the trials found at the far end
The variance around the mean regain trajectory is large and unexplained, exactly as it is for the weight loss.
SUSTAIN-6 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
TRIUMPH-3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Independent analysis puts a KP semaglutide lot at 95.6%, against 94.1% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
The supplement trade found this drug class quickly, and the citations did not improve
A survey of what the meta-analyses support, with the populations named.
SURPASS-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Independent analysis puts a CPC cagrilintide lot at 98.4%, against 96.3% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
Same mass, different molecule: why identity by mass is not identity
An isoaspartate rearrangement changes the molecule and not the mass. A method that confirms identity by molecular weight alone will report it as the parent compound.
STEP 2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
VendorInvestigate result on a Xianning liraglutide lot lands 2.5 points below the supplier’s figure
The report states the gradient, the wavelength and the integration threshold, which is more than most.
The supply gap as a clinical event
A supply interruption is a discontinuation with no notice, no taper and no plan. That is a distinct clinical situation.
SURPASS-2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
STEP 1 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Independent analysis puts a WWB exenatide lot at 97.8%, against 95.3% on the certificate
The result is unremarkable. What the report omits is not.
What happens when the drug is taken away: three randomised answers
The regain trajectories, arm by arm, with the estimands named.
A named analyst is the cheapest quality signal in this trade
Two signatures — one who performed the work, one who approved its release — are the ordinary regulated convention and are almost unknown here.
Why "muscle-sparing" is a marketing term and not a measurement
Grading six widely repeated claims against the studies actually behind them.
Medutest result on a Qingdao orforglipron lot lands 0.8 points below the supplier’s figure
A reminder that a purity figure is the output of a method, and that methods differ.
Independent analysis puts a JEEP orforglipron lot at 95.5%, against 92.7% on the certificate
A reminder that a purity figure is the output of a method, and that methods differ.